JPMorgan Chase & Co. set a €100.00 ($116.28) price target on Merck KGaA (FRA:MRK) in a report issued on Thursday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

A number of other equities research analysts have also recently weighed in on the company. Credit Suisse Group set a €110.00 ($127.91) price target on Merck KGaA and gave the company a buy rating in a report on Friday, September 6th. Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA and gave the company a buy rating in a report on Monday, June 17th. Morgan Stanley set a €96.00 ($111.63) price target on Merck KGaA and gave the company a neutral rating in a report on Tuesday. UBS Group set a €99.00 ($115.12) price target on Merck KGaA and gave the company a neutral rating in a report on Thursday, August 8th. Finally, DZ Bank reaffirmed a buy rating on shares of Merck KGaA in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have assigned a buy rating to the company’s stock. Merck KGaA has a consensus rating of Hold and a consensus price target of €100.94 ($117.38).

Shares of MRK traded up €1.66 ($1.93) during mid-day trading on Thursday, reaching €99.02 ($115.14). 739,433 shares of the company’s stock traded hands. The business’s 50-day moving average price is €94.72 and its 200-day moving average price is €94.64. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: What Are Treasury Bonds?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.